A recent study compared the effectiveness of a new peptide GEP44 to an existing drug, liraglutide, for treating obesity. The study investigated the effectiveness of the new peptide triple agonist in treating obesity and type 2 diabetes. The peptide triple agonist targets three different receptors in the body: the GLP-1 receptor, the neuropeptide Y1 receptor, and the neuropeptide Y2 receptor.

They tested this compound on rats with obesity, and they found that the rats that received GEP44 ate up to 80% less than they typically would, and they lost an average of 12% of their weight within a 16-day study period.

The study found that rats treated with GEP44 lost more weight than those treated with liraglutide. GEP44 did not cause any signs of nausea or vomiting, unlike liraglutide, when tested on rats and shrews.

The GLP-1 receptor is involved in regulating insulin secretion and glucose metabolism, while the neuropeptide Y1 receptor and neuropeptide Y2 receptor are involved in regulating appetite and energy expenditure. By targeting all three receptors, the peptide triple agonist aims to improve glycemic control (i.e., control of blood sugar levels) and promote weight loss.

The study was conducted on mice and involved administering the peptide triple agonist to mice with diet-induced obesity and type 2 diabetes. The results showed that the peptide triple agonist was able to improve glucose tolerance, increase insulin sensitivity, and reduce body weight and fat mass in the mice.

The researchers also compared the effectiveness of the peptide triple agonist to that of existing drugs used to treat type 2 diabetes and obesity, such as liraglutide and lorcaserin. They found that the peptide triple agonist was more effective at promoting weight loss and improving glycemic control than either of these drugs alone.

Overall, the study suggests that the peptide triple agonist has potential as a new treatment option for obesity and type 2 diabetes. However, further research is needed to determine the safety and efficacy of the peptide triple agonist in humans. This is important for longevity because obesity is the number-one cause of preventable shortened life expectancy. A safe and effective weight-loss treatment is a potential game-changer.